Clinical trials recruiting for Epidermal Growth Factor Receptor Gene Mutation
Fewer than 3 recruiting trials found.
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| EPI-326 | 1 |
| Osimertinib | 1 |
| Osimertinib + Chemotherapy | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 2 |
| New Jersey | 2 |
| New York | 2 |
| Tennessee | 2 |
| Texas | 2 |
| Alabama | 1 |
| Arkansas | 1 |
| Delaware | 1 |
| District of Columbia | 1 |
| Georgia | 1 |
| Illinois | 1 |
| Maryland | 1 |
Top cities
Self-screener
Recruiting trials
- A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Related conditions
Trials recruiting for Epidermal Growth Factor Receptor Gene Mutation often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Epidermal Growth Factor Receptor Gene Mutation trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.